IBDEI0IE ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8258,0)
 ;;=E11.21^^55^537^61
 ;;^UTILITY(U,$J,358.3,8258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8258,1,3,0)
 ;;=3^Type 2 diabetes mellitus with diabetic nephropathy
 ;;^UTILITY(U,$J,358.3,8258,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,8258,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,8259,0)
 ;;=E83.41^^55^537^29
 ;;^UTILITY(U,$J,358.3,8259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8259,1,3,0)
 ;;=3^Hypermagnesemia
 ;;^UTILITY(U,$J,358.3,8259,1,4,0)
 ;;=4^E83.41
 ;;^UTILITY(U,$J,358.3,8259,2)
 ;;=^5003002
 ;;^UTILITY(U,$J,358.3,8260,0)
 ;;=E83.42^^55^537^35
 ;;^UTILITY(U,$J,358.3,8260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8260,1,3,0)
 ;;=3^Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,8260,1,4,0)
 ;;=4^E83.42
 ;;^UTILITY(U,$J,358.3,8260,2)
 ;;=^5003003
 ;;^UTILITY(U,$J,358.3,8261,0)
 ;;=E83.51^^55^537^33
 ;;^UTILITY(U,$J,358.3,8261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8261,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,8261,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,8261,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,8262,0)
 ;;=E83.52^^55^537^27
 ;;^UTILITY(U,$J,358.3,8262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8262,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,8262,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,8262,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,8263,0)
 ;;=E87.0^^55^537^30
 ;;^UTILITY(U,$J,358.3,8263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8263,1,3,0)
 ;;=3^Hyperosmolality and hypernatremia
 ;;^UTILITY(U,$J,358.3,8263,1,4,0)
 ;;=4^E87.0
 ;;^UTILITY(U,$J,358.3,8263,2)
 ;;=^5003018
 ;;^UTILITY(U,$J,358.3,8264,0)
 ;;=E87.1^^55^537^31
 ;;^UTILITY(U,$J,358.3,8264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8264,1,3,0)
 ;;=3^Hypo-osmolality and hyponatremia
 ;;^UTILITY(U,$J,358.3,8264,1,4,0)
 ;;=4^E87.1
 ;;^UTILITY(U,$J,358.3,8264,2)
 ;;=^5003019
 ;;^UTILITY(U,$J,358.3,8265,0)
 ;;=E87.5^^55^537^28
 ;;^UTILITY(U,$J,358.3,8265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8265,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,8265,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,8265,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,8266,0)
 ;;=E87.6^^55^537^34
 ;;^UTILITY(U,$J,358.3,8266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8266,1,3,0)
 ;;=3^Hypokalemia
 ;;^UTILITY(U,$J,358.3,8266,1,4,0)
 ;;=4^E87.6
 ;;^UTILITY(U,$J,358.3,8266,2)
 ;;=^60610
 ;;^UTILITY(U,$J,358.3,8267,0)
 ;;=F52.0^^55^537^32
 ;;^UTILITY(U,$J,358.3,8267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8267,1,3,0)
 ;;=3^Hypoactive sexual desire disorder
 ;;^UTILITY(U,$J,358.3,8267,1,4,0)
 ;;=4^F52.0
 ;;^UTILITY(U,$J,358.3,8267,2)
 ;;=^5003618
 ;;^UTILITY(U,$J,358.3,8268,0)
 ;;=F52.21^^55^537^39
 ;;^UTILITY(U,$J,358.3,8268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8268,1,3,0)
 ;;=3^Male erectile disorder
 ;;^UTILITY(U,$J,358.3,8268,1,4,0)
 ;;=4^F52.21
 ;;^UTILITY(U,$J,358.3,8268,2)
 ;;=^5003620
 ;;^UTILITY(U,$J,358.3,8269,0)
 ;;=I12.9^^55^537^25
 ;;^UTILITY(U,$J,358.3,8269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8269,1,3,0)
 ;;=3^Hyp chr kidney disease w stage 1-4/unsp chr kdny
 ;;^UTILITY(U,$J,358.3,8269,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,8269,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,8270,0)
 ;;=I12.0^^55^537^26
 ;;^UTILITY(U,$J,358.3,8270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8270,1,3,0)
 ;;=3^Hyp chr kidney disease w stage 5 chr kidney disease or ESRD
 ;;^UTILITY(U,$J,358.3,8270,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,8270,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,8271,0)
 ;;=K40.90^^55^537^62
 ;;^UTILITY(U,$J,358.3,8271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8271,1,3,0)
 ;;=3^Unil inguinal hernia, w/o obst or gangr, not spcf as recur
